Journal Article

Health-Related Quality of Life and Survival among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy: A Study of Patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort

I. Marion de Boer-van der Kolk, Mirjam A. G. Sprangers, Jan M. Prins, Colette Smit, Frank de Wolf and Pythia T. Nieuwkerk

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 50, issue 2, pages 255-263
Published in print January 2010 | ISSN: 1058-4838
Published online January 2010 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/649216
Health-Related Quality of Life and Survival among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy: A Study of Patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Background

Previous studies have shown that health-related quality of life (HRQL) predicts survival in patients infected with human immunodeficiency virus (HIV). However, these studies predated the highly active antiretroviral therapy (HAART) era, included only a few patients receiving HAART, or had a limited duration of follow-up. This study investigates whether HRQL predicts survival among HIV-infected patients receiving HAART.

Methods

HIV-infected patients participating in the focus group of the AIDS Therapy Evaluation in the Netherlands (ATHENA) study and starting or already receiving HAART completed the Medical Outcomes Study HIV Health Survey at study entry (1 May 1998 through 31 December 2000). The physical health summary (PHS) and mental health summary (MHS) scores were calculated. All-cause mortality was established at 31 March 2008. Kaplan-Meier analysis and Cox regression models were performed to predict survival.

Results

The median follow-up was 8.4 years. Sixty-six patients (11.8%) died during follow-up. We found a significant relation between quartiles of PHS and survival (P<.001 , log-rank test). Of patients with a PHS, 26 (20%) died in quartile 1 (indicating worst HRQL), 17 (13%) died in quartile 2, 10 (8%) died in quartile 3, and 5 (4%) died in quartile 4 (indicating best HRQL) (P<.001 ). The prediction of PHS on survival was independent of other (clinical) parameters (P <.001). No relation was found between MHS and survival (P = .13).

Conclusion

Patient-reported HRQL predicted survival among HIV-infected patients receiving HAART. This information could be highly useful for physicians in determining the prognosis of their patients.

Journal Article.  5195 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.